MX2024004494A - Formulaciones de proteinas quimericas de factor viii y usos de las mismas. - Google Patents

Formulaciones de proteinas quimericas de factor viii y usos de las mismas.

Info

Publication number
MX2024004494A
MX2024004494A MX2024004494A MX2024004494A MX2024004494A MX 2024004494 A MX2024004494 A MX 2024004494A MX 2024004494 A MX2024004494 A MX 2024004494A MX 2024004494 A MX2024004494 A MX 2024004494A MX 2024004494 A MX2024004494 A MX 2024004494A
Authority
MX
Mexico
Prior art keywords
factor viii
formulations
chimeric proteins
viii chimeric
polypeptide
Prior art date
Application number
MX2024004494A
Other languages
English (en)
Spanish (es)
Inventor
Tyler Carlage
Randall Mauldin
Loubna Mzaalak Tazi
Timothy R Mccoy
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of MX2024004494A publication Critical patent/MX2024004494A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2024004494A 2021-10-15 2022-10-14 Formulaciones de proteinas quimericas de factor viii y usos de las mismas. MX2024004494A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163256432P 2021-10-15 2021-10-15
PCT/US2022/078097 WO2023064886A1 (en) 2021-10-15 2022-10-14 Formulations of factor viii chimeric proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2024004494A true MX2024004494A (es) 2024-07-15

Family

ID=84362012

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004494A MX2024004494A (es) 2021-10-15 2022-10-14 Formulaciones de proteinas quimericas de factor viii y usos de las mismas.

Country Status (13)

Country Link
US (1) US20240358800A1 (enExample)
EP (2) EP4415693B1 (enExample)
JP (1) JP2024538091A (enExample)
KR (1) KR20240082408A (enExample)
CN (1) CN118103034A (enExample)
AU (1) AU2022366974A1 (enExample)
CA (1) CA3229979A1 (enExample)
CO (1) CO2024004211A2 (enExample)
ES (1) ES3068733T3 (enExample)
IL (1) IL311969A (enExample)
MX (1) MX2024004494A (enExample)
TW (1) TW202334244A (enExample)
WO (1) WO2023064886A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법

Also Published As

Publication number Publication date
ES3068733T3 (en) 2026-06-02
JP2024538091A (ja) 2024-10-18
EP4740963A2 (en) 2026-05-13
EP4415693A1 (en) 2024-08-21
WO2023064886A1 (en) 2023-04-20
EP4740963A3 (en) 2026-07-22
CA3229979A1 (en) 2023-04-20
EP4415693B1 (en) 2026-02-18
TW202334244A (zh) 2023-09-01
KR20240082408A (ko) 2024-06-10
CN118103034A (zh) 2024-05-28
EP4415693C0 (en) 2026-02-18
CO2024004211A2 (es) 2024-04-18
AU2022366974A1 (en) 2024-05-30
US20240358800A1 (en) 2024-10-31
IL311969A (en) 2024-06-01

Similar Documents

Publication Publication Date Title
MX2024015540A (es) Polipeptidos quimericos para usarse en el tratamiento de la hemofilia a
MX2023015238A (es) Formulaciones de proteinas quimericas del factor viii y usos de las mismas.
HRP20220960T1 (hr) Kimerni proteini faktora viii i njihova upotreba
MX9305729A (es) Formulas de proteinas de liberacion sostenida.
GB2467700A (en) Modified recombinant Factor VIII and von Willebrand Factor and methods of use
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
WO2019191633A3 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
ATE549028T1 (de) Stabile analoga von glp-1
Gangadharan et al. The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells
DE69727149D1 (de) Varianten des vaskulären endothelzellwachsumsfaktors mit antagonistischer wirkung
ATE442373T1 (de) Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
DK0672138T3 (da) Kimære prokoagulante proteiner
US10251940B2 (en) Preparation comprising factor VIII and Von Willebrand factor peptides
DE69739035D1 (de) Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
ATE350049T1 (de) Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1
MX2023001262A (es) Polipéptidos inhibidores del ligando 1 de muerte programada que prolongan la vida media del suero.
ES2054365T3 (es) Inhibicion de la via de la regla del n final en celulas vivas.
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
CO2023000048A2 (es) Conjugados de citoquina
WO2023023588A3 (en) Methods and compositions of inhibiting asprosin mediated orexigenesis and/or glucogenesis
CO2024004211A2 (es) Formulaciones de proteínas quiméricas de factor viii y usos de las mismas
ATE316101T1 (de) Thrombinspaltbare faktor-x-analoga
ATE10364T1 (de) Retro-inverso analoga von c-terminalen pentaund hexapeptiden der verbindung p.